Abstract:Prostate cancer (PCa) is one of the most common epithelial malignant tumors and the fifth leading cause of cancer death in men. An increasing number of studies have demonstrated that N6-methyladenosine (m6A) plays a crucial role in tumorigenesis and tumor development. However, little is known about the role and levels of common m6A regulators and m6A levels in PCa. In this study, we analyzed the characteristic expression of m6A regulators in PCa and castration-resistant prostate cancer (CRPC). UALCAN and cBioPortal were used to estimate the clinical value and genetic alterations of m6A regulators, respectively. The correlation between m6A regulators and androgen receptor (AR) was assessed using Gene Expression Profiling Interactive Analysis (GEPIA) by Pearson correlation statistics. Total m6A levels were detected in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and PCa cell lines. Results showed that the expression of methyltransferase-like 3 (METTL3) and YTH domain family members, namely, YTHDC2, YTHDF1, and YTHDF2 were generally upregulated in PCa, whereas those of fat mass and obesity-associated protein (FTO), AlkB homolog 5 (ALKBH5), and methyltransferase-like 14 (METTL14) were downregulated. The expression of METTL3, METTL14, Wilms' tumor 1-associating protein (WTAP), YTHDC2, YTHDF1, and YTHDF2 were remarkably higher in CRPC with lymph node metastasis than that in CRPC with bone metastasis, whereas ALKBH5, FTO, and YTHDF3 significantly decreased in CRPC with lymph node metastasis tissues. YTHDF1, YTHDF2, and YTHDC2 were positively correlated with the Gleason grades of PCa, and METTL14, FTO, and ALKBH5 were negatively associated with the Gleason classification. M6A regulators were positively correlated with AR. Patients with a genomic alteration of m6A were associated with poor disease-free survival (DFS). The total m6A levels in TRAMP mice increased dramatically compared with those in tumor-free mice, and m6A levels in LNCaP cell lines were higher than DU145 and PC3 cell lines. In summary, METTL3, METTL14, ALKBH5, FTO, YTHDC2, YTHDF1, and YTHDF2 were abnormally expressed in PCa and related to Gleason classification. Changes in m6A levels maybe contributed to the development and progression of PCa.

Role of N 6 ‐methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

The emerging roles of N6-methyladenosine RNA methylation in human cancers

Interaction Between N6-methyladenosine Modification and the Tumor Microenvironment in Colorectal Cancer

The m6A regulators in prostate cancer: molecular basis and clinical perspective

N<SUP>6</SUP>-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Systematic Investigation of Mrna N 6-Methyladenosine Machinery in Primary Prostate Cancer.

The m6A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma

RNA N 6 -methyladenosine modifications in urological cancers: from mechanism to application

Molecular Characterization and Clinical Relevance of N6-Methyladenosine Regulators in Metastatic Prostate Cancer

N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer

RNA m6a Methylation Regulator Expression in Castration-Resistant Prostate Cancer Progression and Its Genetic Associations

The Identification of Critical m6A RNA Methylation Regulators as Malignant Prognosis Factors in Prostate Adenocarcinoma

RNA M6a Methylation Regulators Multi-Omics Analysis in Prostate Cancer.

Role of N6-methyladenosine RNA modification in cancer

Effects of N6-Methyladenosine Modification on Cancer Progression: Molecular Mechanisms and Cancer Therapy

Role of Main RNA Modifications in Cancer: N6-methyladenosine, 5-Methylcytosine, and Pseudouridine

Comprehensive analysis of m6A regulators prognostic value in prostate cancer

The Roles of M6a RNA Modifiers in Human Cancer

The roles of m<SUP>6</SUP>A RNA modifiers in human cancer

Downregulation of N-6-methyladenosine Binding YTHDF2 Protein Mediated by Mir-493-3p Suppresses Prostate Cancer by Elevating N-6-methyladenosine Levels